Ashfield Engage has agreed a deal to incorporate Popit’s digital tools in its patient support programmes, with the aim of improving adherence to treatments.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh